MAR 2 0 2006 W

3-22-06

1FW 281

EXPRESS MAIL NO.: EV452777105US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Park et al. Confirmation No.: 6982

Application No: 10/538,695 Group Art Unit: 2817

Filed: June 10, 2005 Examiner: To Be Assigned.

For: SUSTAINED-RELEASE PREPARATIONS Jones Day Docket No.: 11617-004-999

AND METHOD FOR PRODUCING THE

SAME

INFORMATION DISCLOSURE STATEMENTUNDER 37 C.F.R. §1.56 AND §1.97

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and §1.97 to inform the Patent Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Applicants hereby direct the Examiner's attention to References A01-A18, B01-B06 and C01, listed on the attached Substitute For form 1449/PTO entitled "Information Disclosure Statement by Applicant."

Copies of references B01-B06 and C01 are submitted herewith. Copies of References A01-A18, being U.S. patents, are not submitted herewith pursuant to 37 C.F.R. § 1.98(a)(2)(ii).

Identification of the listed references is not to be construed an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application. Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b) before the mailing of the first Office action on the merits. Therefore, no fee is believed to be due. Should any fee be required, however, please charge such fee to Jones Day Deposit Account No. 50-3013.

Respectfully submitted,

Date: March 20, 2006

(Reg. No.)

Yeahsil Moon

52,042

For: Laura A. Coruzzi

30,742

JONES DAY

222 East 41st Street

New York, New York 10017

(212) 790-9090

Enclosures

Α,

,	MAR 2 0 2006
Substitute for Form	To the state of th

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)

ATTY DOCKET NO.	APPLICATION NO.
11617-004-999	10/538,695
APPLICANT:	
Park et al.	
FILING DATE:	ART UNIT: CONF. NO.:
June 10, 2005	2817 6982

EXAMINER'S INITIALS*		DOCUMENT NUMBER	DATE MM/DD/YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A01	5,451,409	09/19/1995	Rencher et al.	
	A02	5,591,452	01/07/1997	Miller et al.	
	A03	5,807,583	09/15/1998	Kristensen et al.	
	A04	5,849,240	12/15/1998	Miller et al.	
	A05	5,891,471	04/06/1999	Miller et al.	
	A06	5,955,104	09/21/1999	Momberger et al.	
	A07	5,965,163	10/12/1999	Miller et al.	
	A08	5,968,551	10/19/1999	Oshlack et al.	
	A09	6,103,261	08/15/2000	Chasin et al.	
•	A10	6,143,322	11/07/2000	Sackler et al.	
	A11	6,159,501	12/12/2000	Skinhoj	
	A12	6,162,467	12/19/2000	Miller et al.	
	A13	6,254,887	07/03/2001	Miller et al.	
	A14	6,261,599	07/17/2001	Oshlack et al.	
·	A15	6,290,990	09/18/2001	Grabowski et al.	
	A16	6,294,195	09/25/2001	Oshlack et al.	
M	A17	6,306,438	10/23/2001	Oshlack et al.	
	A18	6,335,033	01/01/2002	Oshlack et al.	

			FOREIGN	PATENT DOCUMENTS			
EXAMINER'S INITIALS*		Country Code, Number, Kind of Code (if known)	DATE MM/DD/YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSI	LATION
						YES	NO
	B01	WO 93/15753	08/19/1993	Kaken Pharmaceutical Co. Ltd.			X
	B02	WO 95/14460	06/01/1995	Euroceltique S.A.			
	B03	WO 98/04249	02/05/1998	Asta Medica Aktiengesellschaft			
	B04	WO 99/47128	09/23/1999	Bristol-Myers Squibb Company			
	B05	WO 04/080447	09/23/2004	Euroceltique, S.A.			<u> </u>
	B06	EP 1 125 586	08/22/2001	Tanabe Seiyaku Co., Ltd.			

EXAMINER DATE CONSIDERED	EXAMINER	DATE CONSIDERED
--------------------------	----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	ONE
·	(MAD 0 0 3 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
	MAR 2 0 ZOUR
Sul	bstitute for Formal 49/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)

ATTY DOCKET NO.	APPLICAT	ION NO.
11617-004-999	10/538,695	<u> </u>
APPLICANT:		
Park et al.		
FILING DATE:	ART UNIT:	CONF. NO.:
June 10, 2005	2817	6082

				June 10, 2005	2817	69	982
			FOREIGN P	ATENT DOCUMENTS			
EXAMINER'S INITIALS*		Country Code, Number, Kind of Code (if known)	DATE MM/DD/YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSL	ATION
						YES	NO
		he item (book ,magazine,	journal, etc.,), de	ne of the author (in CAPITAL LETTE) ate, page(s)s, volume, publisher, city (and/or country where pu	blished.,	
	C01			tramadol hydrochloride from matric and Biopharmaceutics, 2001, 52: 23		ryl behe	nate,"

EXAMINER DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.